发明名称 TREATMENT OF DRUG RESISTANCE IN HORMONE-SENSITIVE CANCER
摘要 <p>The present invention provides an ex vivo method for determining whether tumour cells in a patient are, or are likely to become, resistant to a drug that modulates the binding of a steroid hormone to its receptor, comprising: (i) determining the expression level of one or more of the miRNAs listed in Table 1 and/or Table 2 in a tumour cell sample obtained from the patient; and (ii) comparing the expression level of each miRNA to a corresponding control (WT) value, wherein an increase in the cellular expression level of one or more miRNAs listed in Table 1 or a decrease in the cellular expression level of one or more of the miRNAs listed in Table 2 indicates that the tumour cells are, or are likely to become, resistant to the drug. Preferably the tumour cell is a breast cancer cell. Preferably the drug is a selective estrogen receptor modulator (SERM), preferably tamoxifen.</p>
申请公布号 EP2882855(A1) 申请公布日期 2015.06.17
申请号 EP20130747385 申请日期 2013.08.07
申请人 PELICAN HEALTH LIMITED 发明人 JENKINS, PAUL
分类号 C12N15/113;A61K31/7088;A61P35/00;C12N15/11 主分类号 C12N15/113
代理机构 代理人
主权项
地址
您可能感兴趣的专利